Germany's CureVac enrols first participant in pivotal study of COVID-19 vaccine
Follow The Hawk on Google News+ FollowAdvertisement
Berlin: Germany's CureVac announced on Monday that it has enrolled the first participant in the Phase 2b/3 study of its COVID-19 vaccine candidate.
The trial will assess the safety and efficacy in adults and is expected to include more than 35,000 participants in Europe and Latin America, it added in a statement.
Advertisement
—Reuters
Also readFSSAI to initiate action against Bisleri over unsafe water sampleGet The Hawk first on Google
Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.
Advertisement








